<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2332">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081219</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00075245</org_study_id>
    <nct_id>NCT05081219</nct_id>
  </id_info>
  <brief_title>SNIFF - Combo INI+EMPA Trial</brief_title>
  <official_title>Study of Nasal Insulin to Fight Forgetfulness - Combination Intranasal Insulin and Empagliflozin Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed pilot study will provide safety and efficacy preliminary data regarding singular&#xD;
      and combined effects of two therapeutic approaches, intranasal insulin and treatment with the&#xD;
      sodium-glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin, to correct bioenergetic&#xD;
      and vascular dysfunction in adults with preclinical Alzheimer's disease (AD) and amnestic&#xD;
      mild cognitive impairment (aMCI) or early AD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a single site, randomized, double-blind trial comparing the effects&#xD;
      of 4 weeks of intranasal insulin(40 International Units four times daily), empagliflozin (10&#xD;
      mg daily) and combined intranasal insulin (INI) and empagliflozin (empa) compared with&#xD;
      placebo on cerebrospinal fluid (CSF) biomarkers and cognition.&#xD;
&#xD;
      At study entry, participants will be randomized to one of 4 conditions: INI, empa, INI+empa&#xD;
      or placebo. Participants who are cognitively normal but have abnormal elevations of brain&#xD;
      amyloid or who have mild cognitive impairment (MCI) or early Alzheimer's disease (AD) will be&#xD;
      enrolled.&#xD;
&#xD;
      The primary outcome measure will consist of safety (treatment-related serious adverse&#xD;
      events). Secondary outcome measures will consist of cerebrospinal fluid (CSF) biomarkers,&#xD;
      cognition, and cerebral blood flow.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">October 2028</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Neither participants nor site personnel involved in assessing participants will know which dose of insulin is being administered. Exceptions will be the study nurse who is directly involved in preparing the insulin.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment-related Serious Adverse Events as Assessed by CTCAE v5.0</measure>
    <time_frame>Week 8</time_frame>
    <description>Adverse events will be assessed using Common Terminology Criteria for Adverse Events (CTCAE v5.0). The number of participants with grade 3 or greater adverse events that were deemed to be possibly, probably, or definitely related to study treatment will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Preclinical Alzheimer Cognitive Composite 5 (PACC5) Z-Score</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Cognition will be measured using the PACC5 scale, which includes the free/cued selective reminding test, delayed paragraph recall, digit-symbol substitution, mini mental state score, and the category fluency task. The PACC5 is a composite score comprised of measures of global cognition, memory, and executive function. The score reflects an averaged z-score, with higher scores indicating better cognitive performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the 14-item Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog 14) Score</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>A psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 65 (worse), and are added to the mean of the words not immediately recalled (max of 10) and the number of items not recalled after a delay (ranging from 0-10) all total the maximum score of 85. A positive change indicates cognitive worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in amyloid β-peptide (Aβ) 40 (Aβ40) in Cerebrospinal Fluid (CSF)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Cerebrospinal fluid (CSF) samples will be used to measure the levels of amyloid β-peptide (Aβ) 40. CSF Aβ40 is a key Alzheimer's disease (AD) biomarker that reflects pathological aggregation of amyloid in the brain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in amyloid β-peptide (Aβ) 42 (Aβ42) in Cerebrospinal Fluid (CSF)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Cerebrospinal fluid (CSF) samples will be used to measure the levels of amyloid β-peptide (Aβ) 42. CSF Aβ42 is a key Alzheimer's disease (AD) biomarker that reflects pathological aggregation of amyloid in the brain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cerebrospinal Fluid (CSF) Levels of Total Tau</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Cerebrospinal fluid (CSF) samples will be used to measure the levels of total tau protein in the brain to assess impact on brain tau as a relevant Alzheimer's Disease (AD) biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cerebrospinal Fluid (CSF) Levels of Phospho-Tau 181</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Cerebrospinal fluid (CSF) samples will be used to measure the levels of phospho-tau 181 protein in the brain to assess impact on brain tau as a relevant Alzheimer's Disease (AD) biomarker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cerebral Blood Flow (CBF) Using MRI Pseudocontinuous Arterial Spin Labeling (ASL)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Change in CBF in mL/100g/min, calculated as the difference between the pre- and post- ASL flow in response to the study intervention.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Intranasal Insulin and Empagliflozin Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU of intranasal insulin administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily&#xD;
Placebo capsules taken by mouth 30 minutes before breakfast once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin and Intranasal Insulin Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin 10 mg capsules taken by mouth 30 minutes before breakfast once daily&#xD;
40 IU of intranasal insulin diluent (placebo) administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal Insulin and Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU of intranasal insulin administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily&#xD;
Empagliflozin 10 mg capsules taken by mouth 30 minutes before breakfast once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 IU of intranasal insulin diluent (placebo) administered using the Aptar CPS device 30 minutes prior to eating and 30 minutes before bedtime for a total of four (4) times daily&#xD;
Placebo capsules taken by mouth 30 minutes before breakfast once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin (Humulin® R U-100)</intervention_name>
    <description>Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.</description>
    <arm_group_label>Intranasal Insulin and Empagliflozin</arm_group_label>
    <arm_group_label>Intranasal Insulin and Empagliflozin Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.</description>
    <arm_group_label>Empagliflozin and Intranasal Insulin Placebo</arm_group_label>
    <arm_group_label>Intranasal Insulin and Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aptar Pharma CPS Intranasal Delivery Device</intervention_name>
    <description>Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.</description>
    <arm_group_label>Empagliflozin and Intranasal Insulin Placebo</arm_group_label>
    <arm_group_label>Intranasal Insulin and Empagliflozin</arm_group_label>
    <arm_group_label>Intranasal Insulin and Empagliflozin Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Insulin Diluent)</intervention_name>
    <description>Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.</description>
    <arm_group_label>Empagliflozin and Intranasal Insulin Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Capsules)</intervention_name>
    <description>Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.</description>
    <arm_group_label>Intranasal Insulin and Empagliflozin Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 55 to 85 (inclusive)&#xD;
&#xD;
          2. Fluent in English&#xD;
&#xD;
          3. Cognitively normal or diagnosis of amnestic mild cognitive impairment (aMCI) or mild&#xD;
             Alzheimer's disease (AD)&#xD;
&#xD;
          4. Amyloid positive by positron emission tomography (PET) or cerebrospinal fluid (CSF)&#xD;
             criteria&#xD;
&#xD;
          5. Stable medical condition for 3 months prior to screening visit&#xD;
&#xD;
          6. Stable medications for 4 weeks prior to the screening and study visits (exceptions may&#xD;
             be made on a case by case basis by the study physician)&#xD;
&#xD;
          7. Clinical laboratory values must be within normal limits or, if abnormal, must be&#xD;
             judged to be clinically insignificant by the study physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of dementia other than Alzheimer's disease (AD)&#xD;
&#xD;
          2. History of a clinically significant stroke&#xD;
&#xD;
          3. Current evidence or history in past two years of epilepsy, head injury with loss of&#xD;
             consciousness, any major psychiatric disorder including psychosis, major depression,&#xD;
             bipolar disorder&#xD;
&#xD;
          4. Diabetes (type I or type II) insulin-dependent and non-insulin-dependent diabetes&#xD;
             mellitus&#xD;
&#xD;
          5. Current or past regular use of insulin or any other anti-diabetic medication within 2&#xD;
             months of screening visit&#xD;
&#xD;
          6. History of seizure within past five years&#xD;
&#xD;
          7. Pregnancy or possible pregnancy&#xD;
&#xD;
          8. Use of anticoagulants&#xD;
&#xD;
          9. Residence in a skilled nursing facility at screening&#xD;
&#xD;
         10. Use of an investigational agent within two months of screening visit&#xD;
&#xD;
         11. Regular use of alcohol, narcotics, anticonvulsants, anti-parkinsonian medications, or&#xD;
             any other exclusionary medications (exceptions may be made on a case by case basis by&#xD;
             the study physician)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Craft, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences / Wake Forest School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Dahl, RN</last_name>
    <phone>336-713-3432</phone>
    <email>ddahl@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Bohlman, MSL</last_name>
    <phone>336-716-7354</phone>
    <email>sarabrow@wakehealth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences / Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Dahl, RN</last_name>
      <phone>336-713-3432</phone>
      <email>ddahl@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Bohlman, MSL</last_name>
      <phone>336-716-7354</phone>
      <email>sarabrow@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suzanne Craft, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.</citation>
    <PMID>21514249</PMID>
  </reference>
  <reference>
    <citation>Baker H, Spencer RF. Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res. 1986;63(3):461-73.</citation>
    <PMID>3758265</PMID>
  </reference>
  <reference>
    <citation>Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011 Jan;68(1):51-7. doi: 10.1001/archneurol.2010.225. Epub 2010 Sep 13.</citation>
    <PMID>20837822</PMID>
  </reference>
  <reference>
    <citation>Balin BJ, Broadwell RD, Salcman M, el-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol. 1986 Sep 8;251(2):260-80.</citation>
    <PMID>3782501</PMID>
  </reference>
  <reference>
    <citation>Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004 Nov;29(10):1326-34.</citation>
    <PMID>15288712</PMID>
  </reference>
  <reference>
    <citation>Benedict C, Kern W, Schultes B, Born J, Hallschmid M. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab. 2008 Apr;93(4):1339-44. doi: 10.1210/jc.2007-2606. Epub 2008 Jan 29.</citation>
    <PMID>18230654</PMID>
  </reference>
  <reference>
    <citation>Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci. 2002 Jun;5(6):514-6.</citation>
    <PMID>11992114</PMID>
  </reference>
  <reference>
    <citation>Broadwell RD, Balin BJ. Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo. J Comp Neurol. 1985 Dec 22;242(4):632-50.</citation>
    <PMID>2418083</PMID>
  </reference>
  <reference>
    <citation>Cavanna AE, Trimble MR. The precuneus: a review of its functional anatomy and behavioural correlates. Brain. 2006 Mar;129(Pt 3):564-83. Epub 2006 Jan 6. Review.</citation>
    <PMID>16399806</PMID>
  </reference>
  <reference>
    <citation>Chiu SL, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron. 2008 Jun 12;58(5):708-19. doi: 10.1016/j.neuron.2008.04.014.</citation>
    <PMID>18549783</PMID>
  </reference>
  <reference>
    <citation>Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012 Jan;69(1):29-38. doi: 10.1001/archneurol.2011.233. Epub 2011 Sep 12.</citation>
    <PMID>21911655</PMID>
  </reference>
  <reference>
    <citation>Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 1998 Jan;50(1):164-8.</citation>
    <PMID>9443474</PMID>
  </reference>
  <reference>
    <citation>Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004 Mar;3(3):169-78. Review.</citation>
    <PMID>14980532</PMID>
  </reference>
  <reference>
    <citation>De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1971-6. doi: 10.1073/pnas.0809158106. Epub 2009 Feb 2. Erratum in: Proc Natl Acad Sci U S A. 2009 May 5;106(18):7678.</citation>
    <PMID>19188609</PMID>
  </reference>
  <reference>
    <citation>Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ, Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S, Plymate SR, Schwartz MW, Craft S. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol. 2005 Oct;62(10):1539-44.</citation>
    <PMID>16216936</PMID>
  </reference>
  <reference>
    <citation>Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd, Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain. 2008 Dec;131(Pt 12):3311-34. doi: 10.1093/brain/awn288. Epub 2008 Nov 16. Retraction in: Brain. 2014 Jun;137(Pt 6):e283.</citation>
    <PMID>19015157</PMID>
  </reference>
  <reference>
    <citation>Frölich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Türk A, Hoyer S, Zöchling R, Boissl KW, Jellinger K, Riederer P. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna). 1998;105(4-5):423-38.</citation>
    <PMID>9720972</PMID>
  </reference>
  <reference>
    <citation>Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9.</citation>
    <PMID>9236950</PMID>
  </reference>
  <reference>
    <citation>Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 2001 Apr 15;21(8):2561-70.</citation>
    <PMID>11306609</PMID>
  </reference>
  <reference>
    <citation>Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M, Ramirez MJ, Cedazo-Mínguez A. Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. J Alzheimers Dis. 2010;22(2):405-13. doi: 10.3233/JAD-2010-100795.</citation>
    <PMID>20847404</PMID>
  </reference>
  <reference>
    <citation>Hallschmid M, Benedict C, Schultes B, Born J, Kern W. Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond). 2008 Feb;32(2):275-82. Epub 2007 Sep 11.</citation>
    <PMID>17848936</PMID>
  </reference>
  <reference>
    <citation>Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem. 1997 Aug 1;272(31):19547-53.</citation>
    <PMID>9235959</PMID>
  </reference>
  <reference>
    <citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982 Jun;140:566-72.</citation>
    <PMID>7104545</PMID>
  </reference>
  <reference>
    <citation>Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002 Dec 1;7(23):1184-9. Review.</citation>
    <PMID>12547019</PMID>
  </reference>
  <reference>
    <citation>Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes. 1999 Mar;48(3):557-63.</citation>
    <PMID>10078556</PMID>
  </reference>
  <reference>
    <citation>Kristensson K, Olsson Y. Uptake of exogenous proteins in mouse olfactory cells. Acta Neuropathol. 1971;19(2):145-54.</citation>
    <PMID>5126829</PMID>
  </reference>
  <reference>
    <citation>Kupila A, Sipilä J, Keskinen P, Simell T, Knip M, Pulkki K, Simell O. Intranasally administered insulin intended for prevention of type 1 diabetes--a safety study in healthy adults. Diabetes Metab Res Rev. 2003 Sep-Oct;19(5):415-20.</citation>
    <PMID>12951650</PMID>
  </reference>
  <reference>
    <citation>Lee CC, Kuo YM, Huang CC, Hsu KS. Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiol Aging. 2009 Mar;30(3):377-87. Epub 2007 Aug 10.</citation>
    <PMID>17692997</PMID>
  </reference>
  <reference>
    <citation>Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995 Jul-Aug;19(4):541-7.</citation>
    <PMID>7622680</PMID>
  </reference>
  <reference>
    <citation>Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994 Sep;35(9):1528-37.</citation>
    <PMID>8071705</PMID>
  </reference>
  <reference>
    <citation>Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology. 1997 Jun;48(6):1508-10.</citation>
    <PMID>9191756</PMID>
  </reference>
  <reference>
    <citation>Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch Neurol. 2001 Dec;58(12):1985-92. Review.</citation>
    <PMID>11735772</PMID>
  </reference>
  <reference>
    <citation>Pontiroli AE, Alberetto M, Secchi A, Dossi G, Bosi I, Pozza G. Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. Br Med J (Clin Res Ed). 1982 Jan 30;284(6312):303-6.</citation>
    <PMID>6800439</PMID>
  </reference>
  <reference>
    <citation>Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006 Mar;27(3):451-8. Epub 2005 Jun 16.</citation>
    <PMID>15964100</PMID>
  </reference>
  <reference>
    <citation>Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH 2nd, Craft S. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis. 2008 Apr;13(3):323-31.</citation>
    <PMID>18430999</PMID>
  </reference>
  <reference>
    <citation>Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008 Feb 5;70(6):440-8. Epub 2007 Oct 17. Erratum in: Neurology. 2008 Sep 9;71(11):866.</citation>
    <PMID>17942819</PMID>
  </reference>
  <reference>
    <citation>Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis. 2005 Dec;8(3):247-68.</citation>
    <PMID>16340083</PMID>
  </reference>
  <reference>
    <citation>Sakane T, Akizuki M, Taki Y, Yamashita S, Sezaki H, Nadai T. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J Pharm Pharmacol. 1995 May;47(5):379-81.</citation>
    <PMID>7494186</PMID>
  </reference>
  <reference>
    <citation>Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Apr-Jun;25(2):122-7. doi: 10.1097/WAD.0b013e3181f883b7.</citation>
    <PMID>20921876</PMID>
  </reference>
  <reference>
    <citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008 Sep 1;192(1):106-13. doi: 10.1016/j.bbr.2008.02.016. Epub 2008 Feb 17. Review.</citation>
    <PMID>18359102</PMID>
  </reference>
  <reference>
    <citation>Shipley MT. Transport of molecules from nose to brain: transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium. Brain Res Bull. 1985 Aug;15(2):129-42.</citation>
    <PMID>3840049</PMID>
  </reference>
  <reference>
    <citation>Stockhorst U, de Fries D, Steingrueber HJ, Scherbaum WA. Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol Behav. 2004 Oct 30;83(1):47-54. Review.</citation>
    <PMID>15501490</PMID>
  </reference>
  <reference>
    <citation>Thorne RG, Emory CR, Ala TA, Frey WH 2nd. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 1995 Sep 18;692(1-2):278-82.</citation>
    <PMID>8548316</PMID>
  </reference>
  <reference>
    <citation>Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127(2):481-96.</citation>
    <PMID>15262337</PMID>
  </reference>
  <reference>
    <citation>Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem. 2007 Nov 16;282(46):33305-33312. doi: 10.1074/jbc.M610390200. Epub 2007 Sep 13.</citation>
    <PMID>17855343</PMID>
  </reference>
  <reference>
    <citation>Weiss P, Holland Y. Neuronal dynamics and axonal flow, ii. The olfactory nerve as model test object. Proc Natl Acad Sci U S A. 1967 Feb;57(2):258-64.</citation>
    <PMID>16591462</PMID>
  </reference>
  <reference>
    <citation>Worsley KJ, Evans AC, Marrett S, Neelin P. A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab. 1992 Nov;12(6):900-18.</citation>
    <PMID>1400644</PMID>
  </reference>
  <reference>
    <citation>Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci. 2004 Dec 8;24(49):11120-6.</citation>
    <PMID>15590928</PMID>
  </reference>
  <reference>
    <citation>Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta. 2009 May;1792(5):482-96. doi: 10.1016/j.bbadis.2008.10.014. Epub 2008 Nov 5. Review.</citation>
    <PMID>19026743</PMID>
  </reference>
  <reference>
    <citation>Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, Johnston KL, Pilkonis PA. Development of short forms from the PROMIS™ sleep disturbance and Sleep-Related Impairment item banks. Behav Sleep Med. 2011 Dec 28;10(1):6-24. doi: 10.1080/15402002.2012.636266.</citation>
    <PMID>22250775</PMID>
  </reference>
  <reference>
    <citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.</citation>
    <PMID>11556941</PMID>
  </reference>
  <reference>
    <citation>Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.</citation>
    <PMID>16717171</PMID>
  </reference>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 28, 2022</last_update_submitted>
  <last_update_submitted_qc>October 28, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intranasal Delivery of Insulin</keyword>
  <keyword>Cognitive Testing</keyword>
  <keyword>Nasal Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

